Won, K. A., & Spruck, C. (2020). Triple-negative breast cancer therapy: Current and future perspectives (Review). International Journal of Oncology, 57, 1245–1261.
Emens, L. A. (2021). Immunotherapy in triple-negative breast cancer. Cancer Journal, 27, 59–66.
Miles, D., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C., Xu, B., Wardley, A., Kaen, D., Andrade, L., Semiglazov, V., Reinisch, M., Patel, S., Patre, M., Morales, L., Patel, S. L., Kaul, M., Barata, T., & O’Shaughnessy, J. (2021). Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Annals of Oncology, 32, 994–100.
Yadav, R., & Redmond, W. L. (2022). Current clinical trial landscape of OX40 agonists. Current Oncology Reports, 24, 951–960.
Stovgaard, E. S., Kümler, I., List-Jensen, K., Roslind, A., Christensen, I. J., Høgdall, E., Nielsen, D., & Balslev, E. (2022). Prognostic and clinicopathologic associations of LAG-3 expression in triple-negative breast cancer. Applied Immunohistochemistry & Molecular Morphology, 30, 62–71.
Licht, J. D., & Bennett, R. L. (2021). Leveraging epigenetics to enhance the efficacy of immunotherapy. Clinical Epigenetics, 13, 115.
Ashraf, Y., Mansouri, H., Laurent-Matha, V., Alcaraz, L. B., Roger, P., Guiu, S., Derocq, D., Robin, G., Michaud, H. A., Delpech, H., Jarlier, M., Pugnière, M., Robert, B., Puel, A., Martin, L., Landomiel, F., Bourquard, T., Achour, O., Fruitier-Arnaudin, I., … Liaudet-Coopman, E. (2019). Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. Journal for Immunotherapy of Cancer, 7, 29.
Ly, S., Anand, V., El-Dana, F., Nguyen, K., Cai, Y., Cai, S., Piwnica-Worms, H., Tripathy, D., Sahin, A. A., Andreeff, M., & Battula, V. L. (2021). Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. Journal for Immunotherapy of Cancer, 9, e001197.
Young, A., Ngiow, S. F., Gao, Y., Patch, A. M., Barkauskas, D. S., Messaoudene, M., Lin, G., Coudert, J. D., Stannard, K. A., Zitvogel, L., Degli-Esposti, M. A., Vivier, E., Waddell, N., Linden, J., Huntington, N. D., Souza-Fonseca-Guimaraes, F., & Smyth, M. J. (2018). A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Research, 78, 1003–1016.
Lan, J., Lu, H., Samanta, D., Salman, S., Lu, Y., & Semenza, G. L. (2018). Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment. Proceedings of the National Academy of Sciences of the United States of America, 115, E9640–E9648.
CAS PubMed PubMed Central Google Scholar
Chen, W., Shen, L., Jiang, J., Zhang, L., Zhang, Z., Pan, J., Ni, C., & Chen, Z. (2021). Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment. Biomark Research, 9, 59.
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., Özgüroğlu, M., Zou, W., Sandler, A., Enquist, I., Komatsubara, K., Deng, Y., Kuriki, H., Wen, X., McCleland, M., … Spigel, D. R. (2020). Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. New England Journal of Medicine, 383, 1328–1339.
Luo, C., Wang, P., He, S., Zhu, J., Shi, Y., & Wang, J. (2022). Progress and prospect of immunotherapy for triple-negative breast cancer. Frontiers in Oncology, 12, 919072.
Lee, D. H., Choi, S., Park, Y., & Jin, H. S. (2021). Mucin1 and Mucin16: Therapeutic targets for cancer therapy. Pharmaceuticals (Basel), 14, 1053.
Stamm, H., Oliveira-Ferrer, L., Grossjohann, E. M., Muschhammer, J., Thaden, V., Brauneck, F., Kischel, R., Müller, V., Bokemeyer, C., Fiedler, W., & Wellbrock, J. (2019). Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. Oncoimmunology, 8, e1674605.
Niavarani, S. R., Lawson, C., Boudaud, M., Simard, C., & Tai, L. H. (2020). Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+ T-cell functionality. Journal for Immunotherapy of Cancer, 8, e000465.
留言 (0)